(Q43725577)

26 November 2017

title

Tissue insulin sensitivity and body weight in polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

26 November 2017

main subject

1 reference

1 reference

3

1 reference

26 November 2017

Marsden PJ

1

1 reference

26 November 2017

Murdoch AP

series ordinal

2

1 reference

26 November 2017

language of work or name

1 reference

1 August 2001

1 reference

26 November 2017

published in

Clinical Endocrinology

1 reference

26 November 2017

volume

55

1 reference

26 November 2017

issue

2

1 reference

26 November 2017

page(s)

191-199

1 reference

Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Insulin resistance in nonobese patients with polycystic ovarian disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Cellular mechanisms of insulin resistance in polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

The prevalence of polycystic ovaries in women with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Clinical assessment of body hair growth in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Polycystic ovary syndrome: a changing perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Hyperandrogenism, insulin resistance, acanthosis nigricans, and systemic lupus erythematosis associated with insulin receptor antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

The effect of weight loss on sex steroid secretion and binding in massively obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Metabolic profiles and lipoprotein lipid concentrations in non-obese and obese patients with polycystic ovarian disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Adipocyte insulin action in hypogonadotrophic hypogonadism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Effects of obesity on gonadotropin secretion in patients with polycystic ovarian disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Coronary Heart Disease Risk Factors in Women With Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Insulin sensitivity and fertility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

The influence of body weight on lipoprotein lipids in patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

The polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

LH in polycystic ovary syndrome: reproducibility and pulsatile secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01303.X

10.1046/J.1365-2265.2001.01303.X

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference